SAGE Therapeutics (NASDAQ:SAGE) had its price target raised by Stifel Nicolaus from $198.00 to $239.00 in a report issued on Tuesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently commented on SAGE. ValuEngine upgraded SAGE Therapeutics from a buy rating to a strong-buy rating in a report on Wednesday, May 2nd. Cowen reiterated a buy rating on shares of SAGE Therapeutics in a report on Thursday, May 3rd. Canaccord Genuity reiterated a buy rating and issued a $210.00 price objective on shares of SAGE Therapeutics in a report on Thursday, May 3rd. BidaskClub upgraded SAGE Therapeutics from a sell rating to a hold rating in a report on Monday, May 14th. Finally, LADENBURG THALM/SH SH initiated coverage on SAGE Therapeutics in a report on Wednesday, June 6th. They issued a buy rating and a $230.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. SAGE Therapeutics presently has a consensus rating of Buy and an average target price of $199.19.

SAGE Therapeutics opened at $148.36 on Tuesday, according to Marketbeat.com. SAGE Therapeutics has a one year low of $59.57 and a one year high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($1.84) by $1.48. The business had revenue of $90.00 million during the quarter. equities analysts anticipate that SAGE Therapeutics will post -7.99 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. US Bancorp DE boosted its position in shares of SAGE Therapeutics by 5,593.3% in the 2nd quarter. US Bancorp DE now owns 854 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 839 shares during the period. Creative Planning acquired a new stake in shares of SAGE Therapeutics in the 2nd quarter valued at about $210,000. Atria Investments LLC acquired a new stake in shares of SAGE Therapeutics in the 2nd quarter valued at about $218,000. Tiverton Asset Management LLC acquired a new stake in shares of SAGE Therapeutics in the 2nd quarter valued at about $229,000. Finally, World Asset Management Inc acquired a new stake in shares of SAGE Therapeutics in the 2nd quarter valued at about $252,000.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Further Reading: How to Track your Portfolio in Google Finance

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.